Andrew Tsai
Stock Analyst at Jefferies
(0.59)
# 3,773
Out of 4,711 analysts
18
Total ratings
33.33%
Success rate
-15.82%
Average return
Main Sectors:
Stocks Rated by Andrew Tsai
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
RCKT Rocket Pharmaceuticals | Initiates: Buy | $29 | $11.56 | +150.87% | 1 | Dec 18, 2024 | |
MRNS Marinus Pharmaceuticals | Downgrades: Hold | $5 → $0.5 | $0.23 | +117.39% | 1 | Oct 25, 2024 | |
SRPT Sarepta Therapeutics | Initiates: Buy | $165 | $118.97 | +38.69% | 1 | Oct 21, 2024 | |
RLMD Relmada Therapeutics | Upgrades: Buy | $3.5 → $13 | $0.36 | +3,482.25% | 2 | Sep 17, 2024 | |
RAPP Rapport Therapeutics | Initiates: Buy | $35 | $18.07 | +93.69% | 1 | Jul 2, 2024 | |
ANRO Alto Neuroscience | Initiates: Buy | $33 | $3.89 | +748.33% | 1 | Feb 27, 2024 | |
VTGN Vistagen Therapeutics | Upgrades: Buy | $0.2 → $15 | $2.50 | +500.00% | 2 | Dec 7, 2023 | |
LXRX Lexicon Pharmaceuticals | Initiates: Hold | $3 | $0.71 | +319.76% | 1 | Mar 7, 2023 | |
ATHA Athira Pharma | Downgrades: Hold | $32 → $3 | $0.58 | +420.83% | 2 | Jun 23, 2022 | |
BEKE KE Holdings | Upgrades: Overweight | $23 → $16 | $18.38 | -12.95% | 1 | Mar 16, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.70 | +1,076.47% | 1 | Feb 1, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $70 | $83.45 | -16.12% | 2 | Sep 20, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.19 | +2,168.91% | 1 | Sep 1, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $38.63 | -40.46% | 1 | Jun 1, 2020 |
Rocket Pharmaceuticals
Dec 18, 2024
Initiates: Buy
Price Target: $29
Current: $11.56
Upside: +150.87%
Marinus Pharmaceuticals
Oct 25, 2024
Downgrades: Hold
Price Target: $5 → $0.5
Current: $0.23
Upside: +117.39%
Sarepta Therapeutics
Oct 21, 2024
Initiates: Buy
Price Target: $165
Current: $118.97
Upside: +38.69%
Relmada Therapeutics
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $0.36
Upside: +3,482.25%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $18.07
Upside: +93.69%
Alto Neuroscience
Feb 27, 2024
Initiates: Buy
Price Target: $33
Current: $3.89
Upside: +748.33%
Vistagen Therapeutics
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2 → $15
Current: $2.50
Upside: +500.00%
Lexicon Pharmaceuticals
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $0.71
Upside: +319.76%
Athira Pharma
Jun 23, 2022
Downgrades: Hold
Price Target: $32 → $3
Current: $0.58
Upside: +420.83%
KE Holdings
Mar 16, 2022
Upgrades: Overweight
Price Target: $23 → $16
Current: $18.38
Upside: -12.95%
Feb 1, 2022
Initiates: Buy
Price Target: $20
Current: $1.70
Upside: +1,076.47%
Sep 20, 2021
Maintains: Buy
Price Target: $55 → $70
Current: $83.45
Upside: -16.12%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $1.19
Upside: +2,168.91%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $38.63
Upside: -40.46%